# KLOW Peptide: A Research Dossier on the Four-Peptide Anti-Inflammatory Blend > KLOW peptide is a research-only four-peptide blend — KPV, GHK-Cu, BPC-157, and TB-500. Editorial summaries of what the component literature has actually measured. KPV, GHK-Cu, BPC-157, and TB-500 co-formulated in one research vial. What each constituent's studies have measured, what the combination has not, and what the honest gaps are. ## In plain English KLOW peptide is not a single molecule. It is a research-only blend of four distinct peptides — KPV, GHK-Cu, BPC-157, and TB-500 — dissolved together in one vial and used in laboratory settings. The blend itself has never been tested in a controlled study. Every benefit claim traces back to research on one of its four components individually. Here is what those components have been studied for: KPV is the anti-inflammatory arm, shown in cell and animal studies to quiet the inflammatory signals that drive gut and tissue flares. GHK-Cu is the mass-dominant piece — about 62% of the vial by weight — linked to collagen synthesis and broad shifts in gene expression. BPC-157 has been studied mainly in rodent tissue-repair models, where it accelerated tendon and gut healing. TB-500 is a fragment of a protein called thymosin beta-4, most of whose efficacy data come from the full-length protein, not this shorter fragment. None of these peptides is FDA-approved for human use. KLOW is a research chemical. This site documents what the published literature has measured — including the downsides and the open questions. For a plain account of what people report, including the things to watch for, see the [KLOW effects](/effects) page. ## KLOW The KLOW peptide blend is a co-formulation: four chemically distinct research peptides co-dissolved at fixed ratios in a single lyophilized vial. The most widely listed research composition across independent compounders is 80 mg total — GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, and KPV 10 mg. The peptides remain separate molecules; they do not react to form a new compound. The name KLOW is a reverse acronym: K for KPV, L-O for GHK-Cu's tri-letter sequence's copper carrier (conventionally rendered as the middle two), W for the Wolverine-lineage TB-500 and BPC-157 pairing. Whatever the naming rationale, the substance is four peptides — not one. That structural fact governs how every finding in this dossier should be read. KLOW is distinct from the GLOW blend, which contains GHK-Cu, BPC-157, and TB-500 but not KPV. The KPV arm is what separates the two stacks and is the editorial through-line of this dossier. The dealt research lens here is anti-inflammatory: the KPV literature leads, and the other three arms are read in relation to it. ## KLOW peptide blend: the four arms Each component occupies a different node of the tissue-repair signaling network. KPV (Lys-Pro-Val, CAS 67727-97-3, 342.44 Da) is the C-terminal tripeptide of alpha-MSH (alpha-melanocyte-stimulating hormone, a 13-residue anti-inflammatory signaling molecule). It suppresses NF-kappaB (a transcription factor, meaning a molecular switch, that drives inflammatory gene expression) nuclear import in epithelial and immune cells, reduces TNF-alpha, IL-6, and IL-1beta output, and is taken up preferentially into gut cells via PepT1 — a di/tripeptide transporter that is upregulated in inflamed intestinal tissue [1]. GHK-Cu (Gly-His-Lys copper(II), CAS 89030-95-5, 402.92 Da) is a tripeptide chelated to a copper ion, first isolated from human plasma in 1973. It is the mass-dominant component — roughly 62.5% of the canonical vial by weight — and operates mainly at the level of gene expression, with published analyses suggesting it modulates a large fraction of protein-coding genes in fibroblasts, with the strongest signals on extracellular-matrix remodeling, antioxidant defense, and DNA repair [5]. It also supplies copper for lysyl oxidase, the enzyme that crosslinks collagen to give tissue its tensile strength [4]. BPC-157 (GEPPPGKPADDAGLV, CAS 137525-51-0, 1419.53 Da) is a synthetic 15-amino-acid peptide derived from a gastric-juice protein. In rodent models it has been studied extensively for tissue-repair activity: transected Achilles tendon recovery was significantly improved at doses of 10 microg, 10 ng, and 10 pg per rat [2]. It activates the VEGFR2/PI3K/Akt/eNOS angiogenic axis — promoting new blood vessel growth — and modulates the nitric-oxide system. TB-500 (Ac-LKKTETQ, 889.02 Da) is a synthetic heptapeptide marketed as the actin-binding region of the 43-amino-acid native protein thymosin beta-4 (Tbeta4). It is the cytoskeletal arm: the LKKTET motif sequesters G-actin (monomeric actin), a step linked to cell migration and wound closure. Most of the published efficacy data — including the +42% re-epithelialization at four days and +61% at seven days reported in a rat full-thickness wound model [3] — are for full-length native thymosin beta-4, not this shorter fragment. That distinction is not a footnote; it is a material limit on what can be attributed to TB-500 specifically. ## KLOW blend: the honest combination gap No controlled study has tested the four-peptide KLOW blend against monotherapy, against any subset, or against placebo. This is not a gap that will be filled by reading more forums. It is a gap in the published scientific literature, and it means that every claim about what the blend does — as a combination — is a mechanistic extrapolation from the single-component record. A second structural limitation compounds this. The four peptides have markedly different pharmacokinetics (meaning the speed at which they enter cells, circulate, and clear the body). KPV and GHK-Cu are tripeptides that clear relatively quickly; BPC-157 has a short elimination half-life; and the TB-500 fragment behaves differently from native thymosin beta-4. A single co-formulated dose cannot, in principle, hold all four components at matched exposures in the same tissue at the same time. This dossier carries that gap forward explicitly. Every finding here is attributed to the component it belongs to. Blend-level claims are marked for what they are: extrapolations, not measurements. ## KLOW: research status and compliance None of the four components — individually or as the KLOW blend — is FDA-approved for human use. KLOW is a research-only co-formulation, not labeled for human or veterinary administration. BPC-157 was placed by the FDA in category 2 of the 503A bulk-substances review. TB-500, as the synthetic fragment of thymosin beta-4, implicates the WADA Prohibited List (S2, peptide hormones and growth factors), which prohibits thymosin beta-4 at all times in and out of competition [7]. A 2026 Sports Medicine systematic review of approved and unapproved peptide therapies for musculoskeletal conditions concluded that many unapproved peptides — including TB-500 and BPC-157 — show favorable tissue-repair outcomes in animal models, but that rigorous human safety data are scarce and that such compounds operate largely outside regulatory oversight [7]. The first human intravenous safety pilot for BPC-157 alone, published in 2025, administered up to 20 mg to two healthy adults and reported no adverse events — but the n is two, and this is explicitly not an efficacy trial [6]. For what people in research-use communities actually report from the blend — and for the full safety context — the [KLOW research](/research) summary and the [KLOW effects](/effects) page carry the details. --- A midnight-editorial dossier on four separate peptide literatures — each constituent kept to its own studies, the blend's column left blank because no controlled trial has filled it, and nothing here dispensed, dosed, or sold.